Lilly Sepsis Trial Prompts Biotech-Style Jump In Second Quarter
Executive Summary
Wall Street's enthusiastic response to Lilly's potential sepsis therapy may represent the triumph of biotechnology - at least in terms of investor approaches to pharmaceutical stock valuations.
You may also be interested in...
Lilly, Barr Expect Prozac Generics In August 2001 After Appeals Court Ruling
Lilly and Barr expect generic competition to Prozac to arrive in August 2001 after an Aug. 9 Washington D.C. federal appeals court decision in favor of Barr's challenge of a fluoxetine patent.
Lilly, Barr Expect Prozac Generics In August 2001 After Appeals Court Ruling
Lilly and Barr expect generic competition to Prozac to arrive in August 2001 after an Aug. 9 Washington D.C. federal appeals court decision in favor of Barr's challenge of a fluoxetine patent.
Lilly Zyprexa IM Launch Planned For 2001; 2Q Sales Top $550 Mil.
Lilly hopes to introduce an intramuscular formulation of the antipsychotic Zyprexa by mid-2001.